Peapod Bio and Enamine Partner To Speed Drug Discovery

Peapod Bio Inc., announced a strategic collaboration with Enamine, a global supplier of high-quality small molecule libraries. This partnership enables Peapod Bio to offer its clients fully integrated screening campaigns with access to Enamine’s world-class compound collections nearing five million compounds, accelerating hit discovery.

Peapod Bio’s screening technologies, including its proprietary affinity selection mass spectrometry (ASMS) platform powered by polymeric enrichment arrays, efficiently identify inhibitors and binding molecules to virtually any target. Enamine complements this capacity with follow-up chemistry to validate and optimize leads. 

“This collaboration brings together complementary strengths, exceptional chemistry and cutting-edge screening solutions,” said Dr. Zachary Gurard-Levin, PhD, CEO of Peapod Bio. “Together, we’re advancing comprehensive drug discovery solutions.”

“Partnering with Peapod Bio extends the reach of our libraries to new discovery platforms,” added Iryna Iavniuk, CEO of Enamine, US. “Our combined expertise will help researchers accelerate the identification of high value starting points for drug development.”